Thema: US6024961012
MDXG, US6024961012
wall-street-582921_1920.jpg - Foto: THN
MiMedx stock: Surgical growth contrasts with a weaker third quarter
MiMedx said Surgical volume grew in the mid-teens while Wound Care Center volume improved sequentially. Management expects higher adjusted EBITDA in the fourth quarter.
ad-hoc-news.de, heute 00:33 Uhr
MDXG, US6024961012
MiMedx stock: FTC requests more merger documents. Why it ...
MiMedx received the request on October 15, 2026, extending review by 30 days. MiMedx stock has results due October 28, 2026.
ad-hoc-news.de, 23.10.26 03:50 Uhr
MDXG, US6024961012
MiMedx schedules October 28 results. Analysts set a USD ...
Q2 revenue reached USD 64.36 million against USD 63.46 million estimates. Seven analysts rated MiMedx stock Moderate Buy on October 6, 2026.
ad-hoc-news.de, 16.10.26 03:37 Uhr
MiMedx, Strengthens
MiMedx Strengthens Surgical Portfolio with Key Distribution ...
MiMedx US6024961012
boerse-global.de, 06.02.26 12:53 Uhr
New, Clinical
New Clinical Data Bolsters MiMedx’s Case for Insurance ...
